Arrowhead Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arrowhead Pharmaceuticals, Inc.
Vertex has become a biotech investor favorite amid the tumult of 2020, but the potential of its pipeline is now under question.
The Phase I trial of IONIS-ENAC-2.5Rx for cystic fibrosis represents the first time an antisense medicine delivered directly to the lung has shown a significant reduction in ENaC messenger RNA levels.
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.
- Site Specific
- Drug Delivery
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Ablaris Therapeutics, Inc.
- Alvos Therapeutics, Inc. (formerly Mercator Therapeutics, Inc.)
- Arrowhead Research Corporation
- Calando Pharmaceuticals, Inc.